On August 4, Peng Lifeng, Secretary of the Miyun District Committee of Beijing, conducted an on-site inspection in Zhongguancun Miyun Park. During the visit, Peng came to ‌Beijing Yiling Bio-engineering Technology Co., Ltd. (Beijing Yiling Bio)‌, a wholly-owned subsidiary of ‌Yiling Pharma. They gained in-depth insights into the company’s production and operation, product market layout, new product R&D, and plant expansion & investment plans. The delegation also listened to the enterprise’s demands on-site and coordinated solutions to its development challenges. Relevant officials from the Miyun District Committee participated in the inspection, and Shi Jian, General Manager of Beijing Yiling Bio, accompanied the visit.

Peng Lifeng emphasized that high-quality development must be taken as the top priority. Efforts should be made to accelerate the building of a modern industrial system, continuously improve mechanisms for investment project reception and enterprise services, and enhance the park’s industrial leadership and economic support for regional development. It is necessary to foster and expand new quality productive forces, support pharmaceutical enterprises to increase R&D investment, further grow the Life Health Service Industrial Park, leverage resources from scientific research institutes to promote industry-university-research collaborative research, and speed up project implementation to accumulate new momentum for Miyun’s development.
Shi Jian reported the company’s operational achievements to Peng Lifeng. The company’s revenue has maintained continuous growth over the past three years and is expected to reach a new high this year. In May 2026, the company successfully passed the FDA audit, becoming the only pharmaceutical enterprise in Miyun District qualified for direct drug export to the U.S., marking a key breakthrough in its international market. On the R&D front, the company has continuously increased innovation investment, with the Class I innovative drug expected to be launched as early as 2028, which will continuously consolidate the core competitiveness.

After listening to the report, Peng Lifeng required all relevant departments to continue optimizing the business environment, deepen the reform of streamlining administration and delegating powers, improving regulation, and upgrading services, and improve the four-level “butler service package” working mechanism. Policies supporting and benefiting enterprises should be delivered directly and efficiently. Focusing on the full life-cycle needs of enterprises, authorities should help them solve difficulties, go all out to build platforms and introduce resources, so that enterprises can invest with peace of mind, start businesses with ease, and develop with confidence in Miyun.

Going forward, Beijing Yiling Bio will continue to deepen its presence in the domestic market and expand overseas export channels. Leveraging its FDA export qualification, the company will further tap into the global pharmaceutical market. It will also accelerate the R&D process of Class 1 innovative drugs, driving quality improvement and efficiency enhancement through technological innovation. We will actively integrate into the life health industry layout of Zhongguancun Miyun Park, contribute to the cultivation of new quality productive forces through high-quality development, and inject strong biomedical momentum into the construction of a modern industrial system.